PPT-H ybrid coronary revascularization

vs c oronary artery bypass for multivessel disease a metaanalysis Nirav C Patel MD Jonathan M Hemli MD Karthik Seetharam MD Annapoorna Uttara BS Derek R Brinster MD Luigi Pirelli MD Chad . . c. oronary. . d. isease. . d. iagnosed. . at the . t. ime. . of . p. rimary. . PCI for STEMI: . c. omplete. . r. evascularization. . v. ersus. . c. onservative. . s. trategy. . . PRAGUE . bypass grafting in treatment of unprotected left . main stenosis. Nordic–Baltic–British . left main . revascularisation study . (NOBLE. ). A . prospective, randomised, open-label. , non-inferiority trial. –. DEFINE-FLAIR . Justin E Davies, MD, . PhD on behalf of the DEFINE-FLAIR investigators. Hammersmith Hospital, . Imperial College London. F. unctional . L. esion . A. ssessment of . I. ntermediate stenosis to guide . Percutaneous. Coronary Interventions in . Washington State. Chris L. Bryson, MD, MS, COAP Medical Director. Steven M. Bradley, MD; Charles Maynard, PhD. VA Puget Sound Healthcare System and University of Washington. vs. FFR-guided . Coronary Intervention . –. . iFR. -SWEDEHEART. Matthias Götberg, . MD, . PhD. Department of Cardiology, Lund University. Skane. University Hospital. Lund, Sweden. Disclosures. Volcano/Philips: Unrestricted grant to fund . VIABILITY. CORONARY ARTERY DISEASE. ACUTE CORONARY SYNDROME. Undergo . revascularisation. procedures. . Improved survival. Increased number of patients with residual LV dysfunction undergoing progressive LV remodeling and congestive heart failure. Revascularization in Stable Ischemic Heart Disease. Bobby Mathew, MD. LSU Internal Medicine, HO-II. Definitions. Recommendations for revascularization in the setting of symptomatic, stable ischemic heart disease; does not include revascularization in the setting of acute MI. . 2021 ACC/AHA/SCAI Guideline of Coronary Artery Revascularization. Table 1. . Applying. . ACC/AHA Class of Recommendation and Level of Evidence to Clinical Strategies, Interventions, Treatments, or Diagnostic Testing in Patient Care . . Mark Nidorf, Aernoud Fiolet, Arend Mosterd, John Eikelboom, . Astrid Schut, Charley Budgeon, Jan Tijssen, Jan Hein Cornel, Peter Thompson. and the LoDoCo2 Investigators .  . Mark Nidorf has no declaration of interest . S. Elissa Altin, MD. Assistant Professor . Yale University. VA Connecticut. Disclosures. I have no disclosures.. Learning Objectives. Prevalence of angina in women. Prevalence of non-obstructive disease in women. iFR-Swedeheart. 5-year outcome. Matthias Götberg, MD, PhD. Skane. University Hospital, Lund University, Sweden. - on behalf of the . iFR-Swedeheart. investigators. Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below.. . infarction. . NSTEMI Guidelines. Benoit Lattuca. Nîmes . University. Hospital, France. ACTION . Study. Group. benoit.lattuca@gmail.com. Speaker's name : Benoît Lattuca, Nîmes. ☑ I have the . In collaboration with. www.CCClivecases.org. . from. . Cardiac Cath Lab, Mount Sinai Heart, NY, USA. . in. Association with . CME. . MEDI. Q. UEST. . Disclosures. on behalf of the OPTIMUM Investigators. O. utcomes of . P. ercutaneous . Revasculariza. TI. on. for . M. anagement of . S. U. rgically. Ineligible Patients with . M. ultivessel or Left Main Coronary Artery Disease: Primary Results from the .